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Post-kala-azar dermal leishmaniasis (PKDL) is a chronic, stig-
matizing skin condition occurring frequently after apparent
clinical cure from visceral leishmaniasis. Given an urgent
need for new treatments, we conducted a phase IIa safety and
immunogenicity trial of ChAd63-KH vaccine in Sudanese pa-
tients with persistent PKDL. LEISH2a (ClinicalTrials.gov:
NCT02894008) was an open-label three-phase clinical trial
involving sixteen adult and eight adolescent patients with
persistent PKDL (median duration, 30 months; range, 6–
180 months). Patients received a single intramuscular vaccina-
tion of 1  1010 viral particles (v.p.; adults only) or 7.5  1010
v.p. (adults and adolescents), with primary (safety) and second-
ary (clinical response and immunogenicity) endpoints evalu-
ated over 42–120 days follow-up. AmBisome was provided to
patients with significant remaining disease at their last visit.
ChAd63-KH vaccine showed minimal adverse reactions in
PKDL patients and induced potent innate and cell-mediated
immune responses measured by whole-blood transcriptomics
and ELISpot. 7/23 patients (30.4%)monitored to study comple-
tion showed >90% clinical improvement, and 5/23 (21.7%)
showed partial improvement. A logistic regression model
applied to blood transcriptomic data identified immune mod-
ules predictive of patients with >90% clinical improvement. A
randomized controlled trial to determine whether these clinical
responses were vaccine-related and whether ChAd63-KH vac-
cine has clinical utility is underway.
INTRODUCTION
TheWorld Health Organization recognizes the leishmaniases as some
of the most significant global neglected diseases associated with
poverty, with over one billion people at risk of infection, with one
million new cases and over 20,000 deaths reported each year.1,2 These
diseases are caused by infection with one of several species of the pro-
tozoan parasite Leishmania and are transmitted by the bite of female
phlebotomine sand flies. Clinically, disease may be localized to the site
of sand fly bite (cutaneous leishmaniasis [CL]), spread to other skin
(disseminated and diffuse leishmaniasis) or mucosal (mucocutaneous
leishmaniasis) sites, or may involve systemic organs, notably spleen,
liver, and bone marrow (kala azar or visceral leishmaniasis [VL]).3
Post-kala-azar dermal leishmaniasis (PKDL), a chronic skin disease
characterized by nodular or macular lesions that start on the face
and spread to cover the trunk and arms, may develop in up to 50%
of patients previously treated for VL.4 PKDL is thought to play an
important role in sustaining the transmission of VL, especially in
inter-epidemic periods.4–8 Although there has been considerable suc-
cess in reducing the burden of VL in South Asia following the intro-
duction of single-dose liposomal amphotericin B, this drug works less
well in other geographic locations, notably East Africa, which then
has led to a spate of combination drug trials involving antimonials,
miltefosine, paromomycin, and amphotericin B.9 New chemical en-
tities and immune modulators for VL and CL are in the early stages
of clinical development but remain untested in the field.9,10 There
are currently no effective vaccines for the prevention or treatment
of any form of human leishmaniasis.11–13
First-generation Leishmania vaccines composed of whole killed (au-
toclaved) parasites often adjuvanted with Bacillus Calmette-Guérin
(BCG) were not efficacious in a prophylactic setting14,15 but have
shown signs of efficacy as an adjunct to chemotherapy for PKDL16
and American cutaneous leishmaniasis.17,18 Second-generation vac-
cines that have been evaluated in clinical trials to date have been
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recombinant poly-protein vaccines, formulated with a variety of lipid-
based adjuvants primarily aimed at eliciting CD4+ T cell responses
(reviewed in Gillespie et al.,12 Iborra et al.,19 and Moafi et al.20), but
these studies have fallen short of demonstrating efficacy in either a
prophylactic or therapeutic setting. Leishmania as an intracellular
pathogen may also be targeted for immune destruction by effector
mechanisms of CD8+ T cells (including IFNg production and gran-
zyme/granulysin release21), and CD8+ T cell responses have been
associated with vaccine-induced protection in animal models.22–25
Vaccines designed to generate CD8+ T cell responses require a capac-
ity for antigen delivery into the endogenous processing pathway. This
is achieved either by facilitating cross-presentation (e.g., using lipo-
somal delivery) or through endogenous protein synthesis (e.g., naked
DNA or viral vectors; so called “third-generation” vaccines).
We recently described a third-generation adenovirus-vectored vaccine
(ChAd63-KH). ChAd63-KH is based on a well-characterized simian
adenovirus backbone (ChAd63), extensively tested in human volun-
teers and shown to have an excellent safety record.26 ChAd-vectored
vaccines induce potent CD8+ and CD4+ T cell responses and anti-
bodies in humans and are amenable to scalable manufacture to good
manufacturing practices (GMP). ChAd63-KH encodes two Leish-
mania antigens, kinetoplastid membrane protein-11 (K; KMP-11)
and hydrophilic acylated surface protein B (H; HASPB), both with
prophylactic and therapeutic vaccine efficacy when used as monova-
lent vaccines in pre-clinical animal models (mouse, hamster, or
dog).23,24,27 KMP-11 is a highly conserved membrane protein ex-
pressed in promastigotes and amastigotes of all Leishmania examined
to date and is rich in CD8+ T cell epitopes.22 HASPB is expressed by
infective metacyclics and amastigotes28 and has conserved N and C
termini flanking polymorphic repeats. These repeats differ in copy
number and arrangement across isolates of L. donovani,29 although
the functional significance of this is unknown. To increase cross-isolate
coverage, we designed a synthetic KH fusion gene for ChAd63-KH,
engineered to reflect HASPB repeat-sequence diversity.30 Thus,
ChAd63-KH has attributes for a pan-leishmaniasis vaccine.
Results from a first-in-human trial in UK volunteers (ISRCTN:
07766359) indicated that single-dose vaccination with ChAd63-KH
was safe, minimally reactogenic, and induced potent innate and
cell-mediated immune responses.31 Here, we report on the first use
of this vaccine in patients with leishmaniasis. We describe a “window
of opportunity” phase IIa clinical trial demonstrating safety and
immunogenicity of single-dose ChAd63-KH in Sudanese patients
with persistent PKDL.
RESULTS
Study participants and vaccine safety
Thirty-nine patients were screened for eligibility between November
2016 and April 2019 (Figure 1), and 24 patients with the demographic
and baseline biochemical and hematological characteristics shown in
Tables 1 and S1 were enrolled in the study. In each of the adult co-
horts, there were six patients with grade 1 PKDL and two patients
with grade 2 PKDL. In the adolescent cohort, there were two patients
with grade 1 PKDL, five patients with grade 2 PKDL, and one patient
with grade 3 PKDL. Median duration of PKDL in the study popula-
tion was 30 months (range, 6 180 months). In the adult high-dose,
adult low-dose, and adolescent cohorts, respectively, 4 of 8 (50%), 6 of
8 (75%), and 3 of 8 (37.5%) patients had had PKDL for >12 months
duration. Twenty-two of all 24 patients were followed up at the sched-
uled day 90 visit, and 5 of 8 patients in the adolescent cohort were fol-
lowed up to their day 120 scheduled visit (Figure 1).
There was a total of 54 (8 local and 46 systemic) adverse events (AEs)
reported during the study, of which 20 (8 local and 12 systemic) were
considered possibly, probably, or definitely related to vaccination
(Figure 2; Table S1). These included local itch (1 patient), soft swelling
(2 patients), and pain (5 patients) as well as single cases of systemic
malaise, pain, iron-deficiency anemia, and immunological changes
(leucopenia, neutropenia, thrombocytopenia, and thrombocytosis).
Two patients reported headache and feeling hot. Overall, 7 partici-
pants experienced at least one local and 19 experienced at least one
systemic AE, with no significant differences in number of events
per person between cohorts (median adult low dose: 0 local, 2 sys-
temic; median adult high dose: 0 local, 1.5 systemic; adolescent
high dose: 0 local, 1.5 systemic). AEs were limited to grade 1 and 2,
with no grade 3, serious adverse events (SAEs), or suspected unex-
pected serious adverse reactions (SUSARs) reported (Table S1). All
local and systemic AEs reported were deemed to be not serious. Medi-
cation was not required for any of the local AEs reported, and only
two patients had systemic AEs possibly or probably related to vacci-
nation that required medication (one treated with paracetamol for fe-
ver, malaise, headache, and body pain and the other treated with
ferrous sulfate and folic acid for iron-deficiency anemia).
Clinical follow-up
PKDL was subjectively assessed for each individual at each study visit
and scored as percentage change in clinical disease relative to time of
vaccination (Figure 3). Some patients were unable to attend their
formal visits and/or refused treatment at that time due to harvest or
schooling commitments and were examined at unscheduled visits.
Based on the observation of late cure in some patients in the first
two cohorts, the data safety and monitoring board (DSMB) also
approved a formal extension of the follow-up period to assess clinical
response post vaccination from 42 days to 42–90 days. Based on col-
lective analysis of scheduled and unscheduled visits, 11/23 (47.8%)
patients had less than 25% clinical improvement and 5/23 (21.7%)
showed clinical improvement of between 40%–60% over the period
of follow-up. Patient 016 had 50% improvement of their PKDL at
day 42 but was subsequently lost to follow-up. All were treated ac-
cording to protocol, with the exception of the one patient lost to
follow-up. Treatment was not required in 2 of 7 (28.6%) patients in
the adult low-dose cohort (both grade 1 PKDL at vaccination; Figures
3A and 3D), 3 of 8 (37.5%) patients in the adult high-dose cohort (two
grade 1 PKDL and one grade 2 PKDL at vaccination; Figures 3B and
3E), and 2 of 8 (25%) patients in the adolescent cohort (one grade 2
PKDL and one grade 3 PKDL at vaccination; Figures 3C and 3F) who
reached the clinical threshold of >90% improvement in their PKDL.
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Overall, 7 of 23 (30.4%) patients followed to study completion
resolved their PKDL lesions without the need for chemotherapy.
Whole-blood transcriptome prior to and after vaccination
Immune responses in the patient cohort were assessed using whole-
blood transcriptomic analysis (WBTA), comparing pre-vaccination
blood to blood taken at 1-, 3-, and 7-days post vaccination. Differ-
entially expressed genes were identified (Table S2) and used to iden-
tify transcriptional modules significantly associated with vaccination
(Figure 4; Table S3). These data identified three key features of the
response. First, modules associated with an anti-viral signature and
with dendritic cell activation showed a marked dose dependence,
being minimal in patients receiving low-dose vaccine. Second, there
was a near equivalence of these innate responses in adults and
Figure 1. CONSORT diagram for the LEISH2a clinical trial
The CONSORT diagram reports attendance at scheduled inpatient and outpatient visits. Clinical data were also collected for some individuals at additional unscheduled
visits, as shown in Figure 3.
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2368 Molecular Therapy Vol. 29 No 7 July 2021
adolescents receiving high-dose vaccine. Third, modules associated
with B cell responses were prominent only in adolescents. As
approximately 30% of patients resolved their PKDL over the
follow-up period, we sought to identify potential predictors of res-
olution. We used a logistic regression model to identify potential
predictors of patients with >90% clinical resolution, using the Z
scores associated with the blood transcription modules (Figure 4).
This analysis revealed 11 modules (predictive modules sheet in
Table S3), focused on monocyte and dendritic cell attributes, iden-
tified to have highest predictive value for clinical response. Among
these 11 modules, two were also identified as differentially ex-
pressed: LI.M139 (lysosomal/endosomal proteins) and LI.M118.0
(enriched in monocytes) (Table S3).
We also analyzed differentially expressed genes identified at day 1
post vaccination with 7.5 1010 viral particles (v.p.) (Table S3) by In-
genuity Pathway Analysis and for gene set enrichment (using En-
richR). Comparative pathway analysis of differentially expressed
genes in adults (374 UP; 108 DOWN) and adolescents (510 UP;
439 DOWN) showed a high degree of concordance in predicted up-
stream regulators (e.g., IFNG [Z score of 9.169 versus 8.847 for adults
versus adolescents], IFNA2 [Z score of 7.834 versus 7.925], and the
transcription factor IRF7 [Z score of 7.424 versus 7.35]). In EnrichR,
we similarly identified enriched Gene Ontology (GO) and Reactome
pathways related mainly to interferon type I and II signaling, anti-
viral response, myeloid cells, phago-lysosomal functions, and class I
major histocompatibility complex (MHC)-mediated antigen process-
ing and presentation (Table S4), in keeping with the results of the
modular analysis described above. Thus, patients with PKDL appear
to mount effective innate cellular responses to ChAd63-KH.
Finally, we also interrogated our pre-vaccination transcriptomic data
as a means of evaluating whether there were any differences in gene
expression at baseline between those patients who cleared their
PKDL lesions at the end of the study versus those who required
drug treatment. No differentially expressed genes were identified
with false discovery rate (FDR) set at 5%.
CD8+ T cell response following vaccination
IFNg production by CD8+ T cells was measured using ELISpot
following re-stimulation with peptide pools. The frequency of CD8+
T cells producing IFNg specifically in response to KMP-11 (pool 1)
was not significantly different between high- and low-dose vaccinated
adults or between adult and adolescent cohorts (Figure 5A). Overall
ELISpot frequency of responders to KMP-11 after vaccination was
66.6% (16/24), with peak responses in responders ranging from 66–
3,766 spot forming cells (SFC)/million peripheral blood mononuclear
cells (PBMCs; mean, 485; 95% CI, 8.8–962) (Figures 5B and S1). Ten
patients had responses to KMP-11 prior to vaccination of greater than
50 SFC/106 PBMCs, which were of variable magnitude and either
declined or increased post vaccination. Four of the low-dose adult
Table 1. Demographics of study participants
Adults, low dose (n = 8) Adults, high dose (n = 8) Adolescents (n = 8) Total (n = 24)
Sex
Male (%) 7 (87.5) 8 (100.0) 6 (75.0) 21 (87.5)
Female (%) 1 (12.5) 0 (0.0) 2 (25.0) 3 (12.5)
Age (years)a 18.00 (18.00, 19.75) 23.50 (19.50, 32.00) 12.50 (12.00, 14.25) 18.00 (14.75, 23.25)
Height (m)a 1.68 (1.63, 1.71) 1.73 (1.69, 1.76) 1.48 (1.37, 1.57) 1.65 (1.55, 1.72)
Weight (kg)a 54.00 (51.25, 56.75) 58.50 (56.25, 61.00) 34.00 (30.50, 41.88) 52.50 (43.62, 58.25)
Duration PKDL (months)a 30 (6, 57) 51 (18.75, 102) 10 (7, 33) 30 (7, 52.5)
See Table S1 (sheet 1) for further details.
aData presented as median (Q1, Q3).
Figure 2. Summary of AEs reported in this study
AEs that were possibly, probably, or definitely related to vaccination are shown by
category as percentage of total across all three cohorts. (A) Local adverse events
(n = 8). (B) Systemic adverse events (n = 12). Grade 1, mild, green bars. Grade 2,
moderate, yellow bars.
www.moleculartherapy.org
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cohort had immune responses to KMP-11 measured after treatment,
with 2/4 showing some increase compared to their pre-vaccination
response (Figure S1). Responses were comparable in frequency and
magnitude to those seen previously in healthy UK volunteers (Fig-
ure 5C). Cells from adolescent patients were also evaluated for
response to the N-terminal of HASPB (pool 2; 5/8 responders;
mean, 397; 95% CI, 114–908), again showing comparable results
to that seen in UK volunteers (Figures 5D and S2). These data indicate
that PKDL patients respond with similar vigor to the ChAd63-
vectored vaccine antigens as previously observed in healthy UK
volunteers.31 Given the small sample size, we cannot draw any firm
conclusions from these data about the relationship between magni-
tude or specificity of the CD8+ T cell response and clinical outcome.
DISCUSSION
Previous studies in Sudan pioneered the use of immunotherapy with
first-generation vaccines (autoclaved L. major/alum + BCG) in com-
bination with sodium stibogluconate,16,32 but use of a vaccine as
monotherapy in PKDL patients has not been previously reported.
In this phase IIa dose-escalation, age de-escalation clinical trial we
have demonstrated that ChAd63-KH is both safe and immunogenic
in Sudanese PKDL patients, setting the scene for further studies
aimed at evaluating efficacy in a therapeutic setting.
The rationale for using vaccines for therapeutic benefit or for post-
exposure prophylaxis is not new and has been evaluated for a variety
Figure 3. Clinical outcome for LEISH2a
Data are presented for each patient as percentage of initial
PKDL disease over time post vaccination, normalized to the
day of vaccination. (A) Low-dose adult cohort. (B) High-
dose adult cohort. (C) High-dose adolescent cohort. As-
terisks indicate patient receivedconventional treatmentwith
AmBisome. LTFU, lost to follow-up. This patient was
excluded from the assessment of overall cure rate but
included here for completion, as by the time of LTFU the
patient had shown a clinical response of 50%. Dotted line
represents 90% clinical improvement. (D–F) Representative
patient photographs taken pre-vaccination and at the last
follow-up visit are provided for cohort 1 (patient 012; D),
cohort 2 (patient 023; E), and cohort 3 (patient 036; F).
Patient 012 and 036 had widespread small papular lesions
pre-vaccination that became flattened in appearance and in
the case of patient 012 also showed areas of re-/hyper-
pigmentation. Patient 023 also had numerous small papular
lesions as well as more pronounced nodular lesions (e.g.,
near the ear) pre-vaccination, with resolution post vacci-
nation. White boxes are placed to hide patient-identifying
stickers and retain anonymity.
of chronic viral infections, including HIV33 and
HPV34 as well as in cancer.35While some chronic
viral infections may subvert immunity to such an
extent to pose a barrier to therapeutic vaccina-
tion,36 recent evidence suggests that such limita-
tions to vaccine efficacy can be overcome.37 Evidence also suggests
leishmaniasis patients may respond well to therapeutic vaccination.
For example, protective immunity is readily reactivated after drug
cure;11 virally vectored antigen delivery generates effector CD8+
T cells and therapeutic benefit in rodents,30,38 and there have been
encouraging data from human immunochemotherapy trials in leish-
maniasis patients.16,17
PKDL in Sudan has a complex natural history.5–7 In most cases it
emerges within 3–6 months of the cessation of treatment for VL,
reminiscent of an immune reactivation disease,5 although cases also
occur during and even in the absence of prior VL.4,39 In a study of
the natural history of PKDL in 134 children younger than 14 years,40
84% of patients showed spontaneous remission of their disease with a
mean (standard deviation [SD]) of 9.7 (4.7) months. For the remain-
ing 16% (21 patients), duration of PKDL was 16.6 (5.5) months, with
over half of these cases showing either no change or worsening of
PKDL during the first 12 months. Grade or severity of PKDL did
not appear to influence the duration of PKDL, and, unless disease
was very severe, these patients did not require treatment.40 Although
formal time-to-event data are not available, and other age groups have
not been studied systematically, current clinical practice in Sudan is
based on the premise that patients with persistent PKDL for 6 months
or longer duration are not expected to rapidly self-resolve their le-
sions, and such patients are therefore provided with the standard of
care, a protracted course of liposomal amphotericin B (AmBisome;
Molecular Therapy
2370 Molecular Therapy Vol. 29 No 7 July 2021
(legend on next page)
www.moleculartherapy.org
Molecular Therapy Vol. 29 No 7 July 2021 2371
2.5 mg/kg/day for 20 days). Hence, as for other studies evaluating new
drug regimens for PKDL,16,41,42 patients with PKDL of greater than
6 months duration were enrolled for this study (median duration of
PKDL of 30months), with the expectation of a relatively stable disease
over the short window of follow-up. With the caveat that our present
study contains no control arm for self-cure, we are encouraged by the
finding that over a 3- to 4-month period, approximately one-third of
patients resolved their PKDL lesions in the absence of further treat-
ment, with a further 25% showing some clinical improvement. The
extended and variable time frames over which clinical improvements
in PKDL were observed was perhaps not surprising, given the highly
heterogeneous nature of PKDL in this study population. A random-
ized placebo-controlled trial (RCT) of ChAd63-KH in persistent
PKDL patients in Sudan is currently underway (ClinicalTrials.gov:
NCT03969134) to determine whether the clinical improvements
observed in the current study are vaccine-related and, if so, whether
biomarkers can be identified to predict the likelihood of a clinical
response to vaccination. Given the significant costs, patient discom-
fort, and risks associated with current treatment options, should
this level of clinical response be shown to be due to vaccination, it
would represent a major benefit for patients and a welcome new treat-
ment option, particularly if biomarkers were available to stratify pa-
tients for drug or vaccine treatment. While only 20% of patients
Figure 5. CD8+ T cell response to vaccination with
ChAd63-KH
PBMCs from patients collected from d7-d90 post vacci-
nation were stimulated with peptide pools representing the
entire KMP-11 sequence (P1) and the HASPB N terminus
(P2). The number of IFNg-producing cells/million PBMCs
was determined by ELISpot. (A) Peak response by cohort to
P1 after subtraction of unstimulated background and any
pre-vaccination response. (B) Pre-vaccination and peak
post vaccination response per patient to P1 for low-dose
adult (green), high-dose adult (blue), and high-dose ado-
lescents (orange). (C and D) Comparison between patients
in this trial (LEISH2a) and healthy UK volunteer responses
(LEISH1) for response to P1 (C) and P2 (D). Data for LEISH1
are taken from Osman et al.31 Box-and-whisker plots
indicate median, 25th75th quartiles, mix/max values, and
individual patient data points.
in Sudan present with persistent PKDL, in South
Asia persistent disease reflects the norm, and
PKDL patients represent a significant risk to the
regional VL elimination campaign.43–45 The re-
sults from the current study also provide a clear
incentive to evaluate therapeutic vaccination
with ChAd63-KH as a tool for the management of PKDL cases in
South Asia.44
Similar to healthy UK volunteers receiving the same vaccine, PKDL
patients showed no unusual vaccine-induced responses, in keeping
with their general state of health. Indeed, the WBTA indicated that
PKDL patients respond with a vigorous innate immune response,
qualitatively similar to that seen in healthy UK volunteers31 in terms
of GO term enrichment and predicted upstream regulators of gene
expression. A direct quantitative comparison is not possible, however,
due to the use of different platforms for WBTA analysis (Ion Ampli-
Seq Transcriptome Human Gene Expression Kit in this study versus
RNA-seq in Osman et al.31). Module analysis suggested that adoles-
cents with PKDL may generate more pronounced B cell responses
to ChAd63-KH than adults, though the functional significance of
this remains to be determined, and the small sample size and variable
demographics suggest this finding needs confirmation with a larger
sample size and through more detailed phenotypic and functional
analysis of the B cell response. Nevertheless, stronger humoral re-
sponses in adolescents have been observed previously with other vac-
cines (e.g., the quadrivalent HPV vaccine).46,47 Through a logistic
regression model, we also identified a small number of modules
with predictive power for identifying patients reaching the clinical
Figure 4. Whole-blood transcriptomic analysis (WBTA) of patient responses to vaccination with ChAd63-KH
WBTA was conducted using the Ion AmpliSeq Transcriptome Human Gene Expression Kit. Each column represents a different time point (days 1, 3, and 7) after vaccination
in the three study groups (low-dose adults, high-dose adults, high-dose adolescents). Significantly enriched immune-related modules were identified applying the CERNO
test on the adjusted p value-ranked lists of genes generated by DeSeq2 (see Table S2 for module gene lists). Modules are represented by bars in which the proportion of
significantly upregulated and downregulated genes is shown in red and blue, respectively. The gray portion of the bar represents genes that are not significantly differentially
regulated. The significance of module activation is proportional to the intensity of the bar, while the effect size is proportional to its width.
Molecular Therapy
2372 Molecular Therapy Vol. 29 No 7 July 2021
endpoint of >90% improvement. Of note, module LI.M139 contains
only 11 genes encoding endo/lysosomally located proteins and en-
zymes, namely the scavenger receptor CD68; the catabolic enzyme
acid glucosidase (GAA); cathepsins B, D, H, and S (involved in
various aspects of antigen presentation and myeloid cell activation48);
proteins associated with cholesterol transport (NPC2) and glycolipid
catabolism (PSAP); proteins involved in endo/lysosomal protein sort-
ing (AP1S2 and SORT1); and the transporter SLC11A1 (a polymor-
phic divalent metal ion transporter associated with natural resistance
to Leishmania and other intracellular pathogens and enhanced anti-
gen presentation49,50). It remains to be determined to what extent this
vaccine-induced molecular signature relates to vaccine efficacy or is
reflective of underlying immunological or genetic differences in the
response to vaccination in those patients destined to self-resolve their
PKDL. The latter situation may be viewed as somewhat analogous to
the association between leishmanin skin test reaction, self-resolution,
and/or response to therapy observed in PKDL patients.4,16,40
We found that cellular immune responses as measured here using
IFNg ELISpot were on par with those seen with healthy UK volun-
teers. While recognizing that this is not a comparable healthy
endemic control group, the data nevertheless suggest that PKDL pa-
tients do not have underlying immunosuppression. No strong dose-
response relationship was noted across cohorts, as observed in other
studies conducted over similar limited dose ranges.26,31 We observed
that a small number of patients had a pre-existing response to KMP-
11 and the N-terminal of HASPB, and an apparent boosting as well as
apparent loss of response was noted over time post vaccination.
Equally, in the small number of patients where it was measured, there
was an apparent increase in response to these antigens after treat-
ment. While this might reflect the broad range of kinetics observed
in our study of this vaccine in healthy UK volunteers,31 it cannot be
ruled out that the responses observed reflect changes in the underly-
ing immune response to Leishmania in these patients over time. The
immunological follow-up of patients in the placebo arm of our
ongoing RCT should help provide answers to these questions.
This study does have some limitations. First, the immunology of
Sudanese PKDL is complex and still poorly understood,5,6,51,52
though it is reasonably well-established that active disease is associ-
ated with high levels of interleukin (IL)-10 that gives way to enhanced
IFNg and a restoration of skin test reactivity following resolution.5,51
Although the purpose of this study was not to examine heterogeneity
within the immune status of patients with PKDL and its relationship
to disease outcome, we did have the opportunity to examine baseline
gene transcription in whole blood of patients enrolled in this study.
We did not, however, identify any differentially expressed genes
that were related to patient outcome. This result is perhaps not sur-
prising, given the relatively small sample size under study, and further
analysis of this type may be more fruitful in the context of our
ongoing RCT. In addition, the methodology chosen for assessment
of the response to vaccine antigens pre and post vaccination (ELISpot;
the gold standard for assessment of adenoviral vaccine-induced T cell
responses) as well as limitations in the yield of PBMCs meant that we
could not directly measure additional CD4+ or CD8+ T cell-derived T
helper 1 (Th1) and Th2-related cytokines.
In conclusion, this study demonstrating the safety and immunoge-
nicity of ChAd63-KH in PKDL patients represents an important
milestone in the development of a therapeutic vaccine as an addi-
tional tool for PKDL patient management and more broadly encour-
ages further exploration of therapeutic adenovirus-vectored vaccines
for other infectious diseases.
METHODS AND METHODS
Ethics statement
The study was approved by the Review Committees of the Institute of
Endemic Diseases, University of Khartoum, the Sudan National Med-
icines and Poisons Board, and the Department of Biology, University
of York. LEISH2a was sponsored by the University of York. The study
was conducted according to the principles of the current revision of
the Declaration of Helsinki 2008 and International Conference
on Harmonisation (ICH) guidelines for good clinical practice
(GCP; CPMP/ICH/135/95) and was registered as ClinicalTrials.gov:
NCT02894008. All participants provided written informed consent
before enrollment.
Study design and participants
LEISH2awas an open-label three-phase study designed to evaluate the
safety (primary endpoint), clinical response, and immunogenicity
(secondary endpoints) of the investigational vaccine ChAd63-KH in
24 patients with persistent PKDL of greater than 6 months duration.
As this is the first time ChAd63-KHhas been administered to humans
with ongoing persistent PKDL, this sample size allows initial assess-
ment of safety outcomes and determination of the magnitude of the
outcome measures, rather than aiming to obtain statistical signifi-
cance. The number of participants in each part of the study is typical
for early vaccine studies and is considered sufficient to achieve the ob-
jectives of the study. Participants were patients diagnosed with persis-
tent PKDL aged between 18–50 years (adults) or 12–16 years (adoles-
cents). The diagnosis of a case of persistent PKDL was based on a
typical distribution of the skin rash for a duration of 6 months or
more, a temporal relationship to treated kala azar, a reactive serology
test, and exclusion of other skin condition. PKDL lesions were defined
per protocol as grade 1 (scattered maculopapular or nodular lesions,
mainly around the mouth), grade 2 (dense maculopapular or nodular
rash covering most of the face and extending to chest, back, upper
arms and legs), or grade 3 (dense maculopapular or nodular rash
covering most of the body, including hands and feet.).53 Inclusion
criteria included: uncomplicated PKDL of >6 months duration; avail-
ability for the duration of the study; otherwise good health as deter-
mined by medical history, physical examination, results of screening
tests, and the clinical judgment of a medically qualified clinical inves-
tigator; negative for malaria on blood smear; judged able and likely to
comply with all study requirements; willing to undergo screening for
HIV, hepatitis B, and hepatitis C; for females only, willing to undergo
urinary pregnancy tests on the day of screening, on the day of
vaccination (prior to vaccination), and7 and 42days after vaccination.
www.moleculartherapy.org
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Exclusion criteria included:mucosal or conjunctival PKDL; treatment
forPKDLwithin 21days; negative for antibodies in theRK39 strip test;
receipt of a live attenuated vaccine within 60 days or other vaccine
within 14 days of screening; administration of immunoglobulins
and/or any blood productswithin the 3months preceding the planned
administration of the vaccine candidate; history of allergic disease or
reactions likely to be exacerbated by any component of the vaccine or a
history of severe or multiple allergies to drugs or pharmaceutical
agents; any history of severe local or general reaction to vaccination;
for females only, pregnancy, less than 12 weeks postpartum, lactating,
or willingness/intention to become pregnant during the study and for
3 months following vaccination; seropositive for hepatitis B surface
antigen (HBsAg) or hepatitis C (antibodies to HCV); any clinically
significant abnormal finding on screening biochemistry or hematolo-
gy blood tests or urinalysis; any confirmed or suspected immunosup-
pressive or immunodeficient state, including HIV infection; asplenia;
recurrent, severe infections and chronic (more than 14 days)
immunosuppressant medication within the past 6 months; tubercu-
losis, leprosy, or malnutrition (malnutrition in adults defined as a
BMI < 18.5, and in adolescents [12–17 years] as a Z score cutoff value
of < 2 SD); any other significant disease, disorder, or finding
increasing risk to the volunteer, likely to influence the result of the
study, or the volunteer’s ability to participate.
Participants were recruited from an endemic area in Gedaref state,
Sudan, and all study procedures were conducted at the Professor
El-Hassan’s Centre for Tropical Medicine, Dooka, Sudan. Monitoring
of the study was performed under contract by ClinServ (http://www.
clinserv.net).
Vaccine and study procedures
The clinical vaccine lot (B0004) was manufactured by Advent (Pome-
zia, Italy) as described in detail elsewhere.31 The vaccine is a sterile
aqueous buffered solution containing ChAd63-KH at a concentration
of 7.5 1010 v.p./mL. ChAd63-KH was administered as a single dose
in 1mL volume intramuscularly into the deltoidmuscle. The first eight
adult volunteers received 1 1010 v.p., and the subsequent eight adult
volunteers received 7.5  1010 v.p. These doses were previously as-
sessed for safety and immunogenicity in a healthy volunteer phase I
trial31 and are typical of the doses administered in other adenovirus
vaccine trials. Based on a review of the clinical data, eight adolescents
were vaccinated with 7.5 1010 v.p. A cautious stepwise approach was
taken during vaccination, with the first participant at each dose being
followed for 21 days before vaccination of subsequent participants in
that cohort. Patients were monitored in the hospital for 7 days post
vaccination and thereafter as outpatients on days 21, 42, 90, and
120 post vaccination (depending on cohort). An independent
DSMB meeting was held at the end of each cohort to review data
and provide advice to the sponsor regarding continuation of the trial.
Clinical and biochemical test abnormalities were graded according to
the protocol, based on NIH guidelines. Treatment for AEs was pro-
vided as required. The natural history of PKDL in Sudan indicates
that patients with disease persistent for greater than 6 months are un-
likely to self-cure.40 A final endpoint for clinical response was sched-
uled to bemade between day 42 and day 90 (see Results). Patients with
less than 75% improvement were offered standard treatment with
AmBisome (2.5 mg/kg/day for 20 days), those with between 75%–
90% improvement were offered conservative treatment or AmBisome,
and those with greater than 90% clinical improvement were deemed
to not require further treatment. Standard treatment with AmBisome
(20 days; 2.5 mg/kg/day) was provided in the hospital, and patients
were confirmed as clinically cured at the end of treatment. Some pa-
tients defaulted from scheduled visits and were evaluated and treated
at unscheduled visits based on their availability. Decisions to treat and
evaluation of PKDL were performed by two experienced clinicians
based on a subjective assessment of overall clinical improvement in
the patient’s skin condition. Photographs of PKDL lesions were inde-
pendently reviewed to confirm degree of clinical improvement.
WBTA
Whole-blood samples (2.5 mL) were collected into PAXGene tubes
immediately prior to vaccination and at 1-, 3-, and 7-days post
vaccination. All reagents and equipment for these analyses were sup-
plied by Thermo Fisher Scientific and processes carried out per
manufacturers’ protocols, unless otherwise stated. Total RNA was
extracted using the PAXgene Blood RNA kit (PreAnalytiX,
QIAGEN). RNA was quantified using the Qubit 2.0 Fluorometer
with the RNA HS Assay Kit. 50 ng of total RNA was used to
construct sequencing libraries with the Ion AmpliSeq Transcriptome
Human Gene Expression Kit. Libraries were barcoded, purified with
2.5 Agencourt AMPure XP Magnetic Beads (Beckman Coulter),
and then quantified using Ion Library TaqMan Quantitation Kit
on a QuantStudio 5. Libraries were diluted to a concentration of
about 50 pmol and pooled in groups of 8 for sequencing on Ion
PI Chips. Chips were loaded using the Ion Chef System and the
Ion PI Hi-Q Chef Kit. Sequencing was performed on an Ion Proton
Sequencer using Ion PI Hi-Q Sequencing 200 Kit. Data has been
deposited in the Gene Expression Omnibus (GEO) repository .
Differential gene expression analysis was performed using DeSeq2.54
After count data normalization, differential gene expression analysis
was performed using pooled day 0 data from the three study cohorts
as the baseline for all contrasts. Enrichment of blood transcription
modules at each time point in the different groups was assessed
with the tmod R package,55 using as an input the lists of differentially
expressed genes ranked by the p value after multiple test correction, as
computed by DeSeq2. Significance of module enrichment was as-
sessed using the CERNO statistical test (a modification of Fisher’s
combined probability test) and corrected for multiple testing using
the Benjamini-Hochberg correction. In order to identify the modules
with highest correlation to the clinical response, the Z score of each
module was used to train a 1-dimensional Logistic Regression model.
After 100 bootstraps, the modules were ranked according to the
average prediction score. Data analyses were performed by python
scripts using the scikit-learn python library.56 Gene set enrichments
were performed in EnrichR,57 and pathway analysis was conducted
using IPA (QIAGEN, https://digitalinsights.qiagen.com/products/
ingenuity-pathway-analysis).58
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Assessment of vaccine-induced immunity
Ex vivo re-stimulation of frozen PBMCs to elicit vaccine-induced
CD8+ T cell responses was performed (at days 0, 21, 42, and 90) us-
ing Multiscreen IP ELISpot plates (Millipore), human IFNg SA-APL
antibody kits (Mabtech), and BCIP-NBT-plus chromogenic sub-
strate (Moss) as previously described.31 Peptide re-stimulation was
restricted to peptide pools corresponding to the entire KMP-11
sequence and the N-terminal conserved domain of HASPB1 (pools
1 and 231) due to limitations in cells obtained from patients. Pep-
tides were 8- to 11-mer truncated sets as fully described in Osman
et al.,31 largely restricting recognition to CD8+ T cells. Responses to
medium-only negative controls were subtracted, and responses >50
SFC/million above the pre-vaccination response were regarded as
positive. Antibody responses will be reported at a later date due
to inaccessibility of trial samples at the current time due to
COVID-19.
Statistical analysis
Twenty-four was chosen as an appropriate sample size for this phase
IIa vaccine study to evaluate safety outcomes and explore the magni-
tude of outcome measures. It was not formally derived to show signif-
icant differences from any comparisons. All baseline data were sum-
marized descriptively. Continuous measures are reported as averages
(n, mean, SDs, median, interquartile range (IQR), min, max), and cat-
egorical data are reported as counts and percentages. Number of local
and systemic AEs per participant are presented as median, minimum,
maximum, and IQR. The median number of AEs per participant
(separately for local and systemic events) was compared between
groups using the Mann-Whitney U test (three comparisons for
each type of event). Analyses were performed using Stata v1659 and
R v3.5.3.60 ELISpot data were evaluated for normality using the D’Ag-
nostino and Pearson test and compared using non-parametric Kol-
mogorov-Smirnov test. All analysis was performed in GraphPad
Prism for MacOS v8.4.1.
Data availability
Transcriptomic data have been deposited in the Gene Expression
Omnibus (GEO) repository with accession number GEO:
GSE156645 and are available from: https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE156645.
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